Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: Eli Lilly operates in a single significant business segment: pharmaceutical products. The company discovers, develops, manufactures, and sells products globally, with major product groups including neuroscience (e.g., Prozac, Zyprexa), endocrine (e.g., Humulin, Humalog), anti-infectives, cardiovascular agents, and oncology products. The company also maintains an animal health division (Elanco).
Strategic Shift: In January 1999, the company completed the sale of its PCS Health Systems business (health care management services) to Rite Aid Corporation for approximately $1.6 billion. PCS results are reported as discontinued operations.
Key Financial Metrics
| Metric | 1998 Value | 1997 Value |
|---|---|---|
| Total Sales | $9.24 billion | $7.99 billion |
| Income from Continuing Operations | $2.10 billion ($1.87 per share) | $2.02 billion ($1.78 per share) |
| Adjusted Income (Excluding Unusual Items) | $2.17 billion ($1.94 per share) | $1.83 billion ($1.62 per share) |
| Gross Margin | 78.2% | 75.6% |
| Research & Development Expenses | $1.74 billion | $1.37 billion |
| Marketing & Administrative Expenses | $2.66 billion | $2.24 billion (approx.) |
| Effective Tax Rate | 21.3% | 30.5% |
| Total Debt | $2.37 billion | $2.56 billion (approx.) |
| Cash, Equivalents & Short-term Investments | $1.60 billion | $2.02 billion |
| Capital Expenditures | $419.9 million | $366.3 million (approx.) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% to $9.24 billion, driven by a 20% increase in U.S. sales and a 9% increase in international sales. Growth was fueled by volume (15.3%) and price increases (2.1%), partially offset by unfavorable exchange rates (-1.8%).
- Product Performance:
- Zyprexa: Sales surged 98% to $1.44 billion.
- Prozac: Sales increased 10% to $2.81 billion, though growth slowed due to generic competition and wholesaler stocking patterns.
- Humalog: Sales jumped 91% to $129.6 million.
- Declines: Anti-infectives sales fell 9% and Axid sales dropped 20% due to generic competition.
- Profitability: Income from continuing operations rose 4% to $2.10 billion. Excluding unusual items, earnings grew 19%. Gross margin improved to 78.2% due to favorable product mix and productivity.
- Unusual Items:
- 1998: A one-time charge of $127.5 million was recorded for acquired in-process technology related to a collaboration with ICOS Corporation (sexual dysfunction treatment).
- 1997: Included a $631.8 million gain from the sale of the DowElanco joint venture and a $97.8 million asset impairment charge.
- Debt and Liquidity: Total debt decreased by $186.8 million. Cash reserves declined primarily due to the completion of a $2 billion share repurchase program (28.3 million shares acquired in 1998).
Guidance, Outlook, and Risks
- Outlook: Management expects continued strong sales growth for Zyprexa, ReoPro, Gemzar, and Evista in 1999, though at lower percentage rates than 1998. Prozac sales are expected to show only slight growth. Gross margins are anticipated to improve further due to product mix and the expiration of a royalty obligation on insulin products.
- Expense Guidance: R&D expenses are expected to increase at a lower rate in 1999, approximating sales growth. Marketing expenses are also expected to rise at a significantly lower rate due to expense-management programs.
- Tax Rate: The company expects a sustainable effective tax rate in the range of 22% to 22.5% under present law.
- Capital Allocation: The company plans to repurchase approximately $1 billion of shares in 1999 and expects to use proceeds from the PCS sale for general corporate purposes. Dividends were increased to an annual rate of $0.92 per share.
- Key Risks:
- Patent Litigation: Significant ongoing litigation regarding Prozac patents (expiring 2001 and 2003) with generic manufacturers (Barr, Geneva, Teva, etc.). An unfavorable outcome could materially adversely affect financial position.
- Competition: Intense price competition from generic drugs upon patent expiration and from competitors in branded markets.
- Regulatory Environment: Government-mandated cost containment, price controls, and Medicaid rebate programs (which reduced 1998 sales by $278.6 million).
- Year 2000 (Y2K): Estimated total program costs between $160 million and $190 million. While 95% of critical applications are renovated, failure to correct issues could disrupt operations.
- Foreign Exchange: Exposure to currency fluctuations, particularly the strengthening U.S. dollar against the yen and European currencies.
Investor Verification Checklist
- Prozac Patent Litigation Status: Verify the current status of appeals regarding the Barr and Geneva lawsuits and the progress of suits against Teva, Zenith, and others, as these directly impact future revenue from the company's largest product.
- PCS Sale Proceeds: Confirm the timing and utilization of the $1.6 billion cash proceeds from the PCS sale, specifically regarding debt reduction or share buybacks.
- ICOS Collaboration Expense: Review the impact of the $127.5 million one-time charge on future R&D pipelines and the potential commercial viability of the PDE5 inhibitor.
- Generic Competition Impact: Assess the trajectory of sales declines for Axid and anti-infectives to gauge the speed of market share erosion in non-patent-protected categories.
- Y2K Remediation Costs: Monitor actual spending against the $160-$190 million estimate and verify the completion of contingency plans for critical vendors and supply chains.